Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas.

Field MG, Kuznetsov JN, Bussies PL, Cai L, Alawa KA, Decatur C, Kurtenbach S, Harbour JW.

Clin Cancer Res. 2019 Jul 8. pii: clincanres.0366.2019. doi: 10.1158/1078-0432.CCR-19-0366. [Epub ahead of print]

PMID:
31285370
2.

HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma.

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM.

Clin Cancer Res. 2019 Jun 21. pii: clincanres.3382.2018. doi: 10.1158/1078-0432.CCR-18-3382. [Epub ahead of print]

PMID:
31227503
3.

Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a.

Anbunathan H, Verstraten R, Singh AD, Harbour JW, Bowcock AM.

Clin Cancer Res. 2019 Jun 21. pii: clincanres.3052.2018. doi: 10.1158/1078-0432.CCR-18-3052. [Epub ahead of print]

PMID:
31227497
4.

Genomic evolution of uveal melanoma arising in ocular melanocytosis.

Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, Harbour JW.

Cold Spring Harb Mol Case Stud. 2019 Jun 11. pii: mcs.a004051. doi: 10.1101/mcs.a004051. [Epub ahead of print]

5.

Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma.

Fan KC, Tran KD, Harbour JW, Dubovy SA, Patel NA, Albini TA.

J Ophthalmic Inflamm Infect. 2019 Jun 10;9(1):11. doi: 10.1186/s12348-019-0177-8.

6.

An Eight-Year-Old Girl Presents With Two Weeks of Vision Loss and Nightly Headaches.

Scott NL, Tran KD, Cernichiaro-Espinosa LA, Russell JF, Hinkle JW, Harbour JW, Dubovy SR, Berrocal AM.

Ophthalmic Surg Lasers Imaging Retina. 2019 May 1;50(5):314-317. doi: 10.3928/23258160-20190503-09.

PMID:
31100163
7.

Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study.

Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA 3rd, Baumal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y.

Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):221-227. doi: 10.3928/23258160-20190401-04.

8.

Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.

Dean MK, Studenski MT, Paez-Escamilla MA, Walter SD, Kwon D, Markoe AM, Harbour JW, Samuels SE.

Brachytherapy. 2019 May - Jun;18(3):404-410. doi: 10.1016/j.brachy.2019.01.005. Epub 2019 Feb 20.

PMID:
30797699
9.

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS.

Am J Hematol. 2019 Apr;94(4):455-460. doi: 10.1002/ajh.25414. Epub 2019 Feb 4.

PMID:
30663807
10.

Drug and disease signature integration identifies synergistic combinations in glioblastoma.

Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG.

Nat Commun. 2018 Dec 14;9(1):5315. doi: 10.1038/s41467-018-07659-z.

11.

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK.

J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341. doi: 10.1093/jnci/djy171.

PMID:
30517737
12.

CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides.

Husnain M, Mackrides N, Vega F, Paez-Escamilla M, Markoe AM, Harbour JW, Lossos IS.

Leuk Lymphoma. 2019 May;60(5):1308-1311. doi: 10.1080/10428194.2018.1526376. Epub 2018 Nov 14. No abstract available.

PMID:
30424702
13.

Diagnosis of Bilateral Retinocytoma in an Adolescent Patient Using Multimodal Imaging and Genetic Testing.

Paez-Escamilla M, Walter SD, Ramaiya KJ, Harbour JW.

Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 1;49(10):812-814. doi: 10.3928/23258160-20181002-11.

PMID:
30395669
14.

ChIPprimersDB: a public repository of verified qPCR primers for chromatin immunoprecipitation (ChIP).

Kurtenbach S, Reddy R, Harbour JW.

Nucleic Acids Res. 2019 Jan 8;47(D1):D46-D49. doi: 10.1093/nar/gky813.

15.

Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.

Harbour JW, Paez-Escamilla M, Cai L, Walter SD, Augsburger JJ, Correa ZM.

Am J Ophthalmol. 2019 Jan;197:168-179. doi: 10.1016/j.ajo.2018.08.045. Epub 2018 Sep 7.

PMID:
30195895
16.

Persistent fetal vasculature presenting with axial elongation and platyphakia.

Lin J, Paez-Escamilla M, Teira LE, Fallas B, Harbour JW.

J AAPOS. 2019 Feb;23(1):51-53. doi: 10.1016/j.jaapos.2018.06.005. Epub 2018 Aug 31.

PMID:
30176292
17.

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.

Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, Harbour JW.

Am J Ophthalmol. 2018 Nov;195:154-160. doi: 10.1016/j.ajo.2018.07.045. Epub 2018 Aug 6.

PMID:
30092184
18.

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.

Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC.

Leukemia. 2018 Aug;32(8):1834-1837. doi: 10.1038/s41375-018-0126-9. Epub 2018 Apr 2. No abstract available.

19.

Congenital Hypertrophy of the Retinal Pigment Epithelium Presenting With Secondary Choroidal Neovascularization.

Garoon RB, Harbour JW.

Ophthalmic Surg Lasers Imaging Retina. 2018 Apr 1;49(4):276-277. doi: 10.3928/23258160-20180329-12.

PMID:
29664987
20.

Anterior Chamber Chemotherapy in Retinoblastoma-Necessary But Not Sufficient for Aqueous Seeding Control-Reply.

Harbour JW, Paez-Escamilla M.

JAMA Ophthalmol. 2018 May 1;136(5):597. doi: 10.1001/jamaophthalmol.2018.0639. No abstract available.

PMID:
29596550
21.

RETINOCYTOMA WITH VITREOUS SEEDING: NEW INSIGHTS FROM ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY AND HIGH-RESOLUTION POSTERIOR SEGMENT ULTRASONOGRAPHY.

Garoon RB, Medina CA, Scelfo C, Harbour JW.

Retin Cases Brief Rep. 2018 Feb 21. doi: 10.1097/ICB.0000000000000732. [Epub ahead of print]

PMID:
29470300
22.

Retinoblastoma With Endophytic and Exophytic Features.

Paez-Escamilla M, Bagheri N, Harbour JW.

JAMA Ophthalmol. 2018 Jan 11;136(1):e175064. doi: 10.1001/jamaophthalmol.2017.5064. Epub 2018 Jan 11. No abstract available.

PMID:
29327048
23.

Punctuated evolution of canonical genomic aberrations in uveal melanoma.

Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, Harbour JW.

Nat Commun. 2018 Jan 9;9(1):116. doi: 10.1038/s41467-017-02428-w.

24.

Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains.

Peng H, Prokop J, Karar J, Park K, Cao L, Harbour JW, Bowcock AM, Malkowicz SB, Cheung M, Testa JR, Rauscher FJ 3rd.

Cancer Res. 2018 Mar 1;78(5):1200-1213. doi: 10.1158/0008-5472.CAN-17-2876. Epub 2017 Dec 28.

25.

Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing.

Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dubovy SR, Harbour JW, Karp CL.

JAMA Ophthalmol. 2017 Dec 1;135(12):1434-1437. doi: 10.1001/jamaophthalmol.2017.4837.

26.

Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC.

Blood. 2018 Jan 18;131(3):328-341. doi: 10.1182/blood-2017-06-789669. Epub 2017 Nov 7.

27.

Letter to the Editor: Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas.

Harbour JW, Paez-Escamilla M.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5444. doi: 10.1167/iovs.17-22603. No abstract available.

PMID:
29059310
28.

Liquid Biopsy in Retinoblastoma.

Harbour JW.

JAMA Ophthalmol. 2017 Nov 1;135(11):1231. doi: 10.1001/jamaophthalmol.2017.4094. No abstract available.

PMID:
29049432
29.

Multimodal Imaging of Astrocytic Hamartomas Associated With Tuberous Sclerosis.

Schwartz SG, Harbour JW.

Ophthalmic Surg Lasers Imaging Retina. 2017 Sep 1;48(9):756-758. doi: 10.3928/23258160-20170829-11.

PMID:
28902337
30.

An international survey of classification and treatment choices for group D retinoblastoma.

Scelfo C, Francis JH, Khetan V, Jenkins T, Marr B, Abramson DH, Shields CL, Pe'er J, Munier F, Berry J, Harbour JW, Yarovoy A, Lucena E, Murray TG, Bhagia P, Paysse E, Tuncer S, Chantada GL, Moll AC, Ushakova T, Plager DA, Ziyovuddin I, Leal CA, Materin MA, Ji XD, Cursino JW, Polania R, Kiratli H, All-Ericsson C, Kebudi R, Honavar SG, Vishnevskia-Dai V, Epelman S, Daniels AB, Ling JD, Traore F, Ramirez-Ortiz MA.

Int J Ophthalmol. 2017 Jun 18;10(6):961-967. doi: 10.18240/ijo.2017.06.20. eCollection 2017.

31.

Fluorescein angiography findings in diffuse retinoblastoma: two case reports with clinicopathologic correlation.

Fernandez MP, Al-Holou SN, Fischer O, Murray T, Harbour JW, Dubovy SR, Berrocal AM.

J AAPOS. 2017 Aug;21(4):337-339.e2. doi: 10.1016/j.jaapos.2017.03.013. Epub 2017 Jul 8. Review.

PMID:
28694215
32.

Incorporating Clinical, Histological, and Genetic Parameters for Choroidal Melanoma Prognostication-Reply.

Harbour JW.

JAMA Ophthalmol. 2017 Jul 1;135(7):819-820. doi: 10.1001/jamaophthalmol.2017.1393. No abstract available.

PMID:
28542673
33.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

34.

Preclinical Acute Ocular Safety Study of Combined Intravitreal Carboplatin and Etoposide Phosphate for Retinoblastoma.

Mohney BG, Elner VM, Smith AB, Harbour JW, Smith BD, Musch DC, Smith SJ.

Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 1;48(2):151-159. doi: 10.3928/23258160-20170130-09.

PMID:
28195618
35.

ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.

Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, Chen S, Yang H, He Y, Li J, Guo Y, Zhang W, Hajiramezanali E, An H, Fajardo D, Harbour JW, Ruan Y, Nimer SD, Yu P, Chen X, Xu M, Yang FC.

Sci Adv. 2017 Jan 20;3(1):e1601602. doi: 10.1126/sciadv.1601602. eCollection 2017 Jan.

36.

Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma-Reply.

Harbour JW.

JAMA Ophthalmol. 2017 Feb 1;135(2):175-176. doi: 10.1001/jamaophthalmol.2016.5109. No abstract available.

PMID:
28056125
37.

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.

Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S, Harbour JW.

Oncotarget. 2016 Sep 13;7(37):59209-59219. doi: 10.18632/oncotarget.10962.

38.

An Iris Tumor.

Rao RC, Harbour JW.

JAMA Ophthalmol. 2016 Sep 1;134(9):1063-4. doi: 10.1001/jamaophthalmol.2016.0924. No abstract available.

39.

A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.

Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA.

Melanoma Res. 2016 Oct;26(5):481-6. doi: 10.1097/CMR.0000000000000274. Review.

40.

ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.

Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY.

Cancer Cell. 2016 Jun 13;29(6):889-904. doi: 10.1016/j.ccell.2016.04.015. Epub 2016 Jun 2.

41.

Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.

Walter SD, Chao DL, Feuer W, Schiffman J, Char DH, Harbour JW.

JAMA Ophthalmol. 2016 Jul 1;134(7):734-40. doi: 10.1001/jamaophthalmol.2016.0913.

42.

Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW.

JAMA Ophthalmol. 2016 Jul 1;134(7):728-33. doi: 10.1001/jamaophthalmol.2016.0903.

43.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

44.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

45.

Uveal and Conjunctival Melanoma: Close Together-but Only Distantly Related.

Harbour JW.

Oncology (Williston Park). 2016 Jan;30(1):44, 48. No abstract available.

46.

EMT-associated factors promote invasive properties of uveal melanoma cells.

Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG.

Mol Vis. 2015 Aug 25;21:919-29. eCollection 2015.

47.

Spectral-Domain Optical Coherence Tomography of Presumed Solitary Circumscribed Retinal Astrocytic Proliferation Versus Astrocytic Hamartoma.

Schwartz SG, Harbour JW.

Ophthalmic Surg Lasers Imaging Retina. 2015 May;46(5):586-8. doi: 10.3928/23258160-20150521-13.

PMID:
26057765
48.

Epigenetic reprogramming of melanoma cells by vitamin C treatment.

Gustafson CB, Yang C, Dickson KM, Shao H, Van Booven D, Harbour JW, Liu ZJ, Wang G.

Clin Epigenetics. 2015 Apr 29;7:51. doi: 10.1186/s13148-015-0087-z. eCollection 2015.

49.

Hydroxyapatite versus polyethylene orbital implants for patients undergoing enucleation for uveal melanoma.

Chao DL, Harbour JW.

Can J Ophthalmol. 2015 Apr;50(2):151-4. doi: 10.1016/j.jcjo.2014.11.007.

PMID:
25863856
50.

Gene expression profiling and regression rate of irradiated uveal melanomas.

Rao RC, Khan M, Badiyan SN, Harbour JW.

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):333-7. doi: 10.3928/23258160-20150323-06.

Supplemental Content

Loading ...
Support Center